ID | 66204 |
FullText URL | |
Author |
Bian, Zhihong
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Hu, Xinran
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Liu, Xia
Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Yu, Haibo
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Bian, Yuting
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Sun, Hongming
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Fukui, Yusuke
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Morihara, Ryuta
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
researchmap
Ishiura, Hiroyuki
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Yamashita, Toru
Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
ORCID
Kaken ID
researchmap
|
Abstract | Background:Alzheimer’s disease (AD) is characterized by cognitive dysfunction and memory loss that is accompanied by pathological changes to white matter. Some clinical and animal research revealed that AD combined with chronic cerebral hypoperfusion (CCH) exacerbates AD progression by inducing blood-brain barrier dysfunction and fibrinogen deposition. Rivaroxaban, an anticoagulant, has been shown to reduce the rates of dementia in atrial fibrillation patients, but its effects on white matter and the underlying mechanisms are unclear.
Objective:The main purpose of this study was to explore the therapeutic effect of rivaroxaban on the white matter of AD+CCH mice. Methods:In this study, the therapeutic effects of rivaroxaban on white matter in a mouse AD+CCH model were investigated to explore the potential mechanisms involving fibrinogen deposition, inflammation, and oxidative stress on remyelination in white matter. Results:The results indicate that rivaroxaban significantly attenuated fibrinogen deposition, fibrinogen-related microglia activation, oxidative stress, and enhanced demyelination in AD+CCH mice, leading to improved white matter integrity, reduced axonal damage, and restored myelin loss. Conclusions:These findings suggest that long-term administration of rivaroxaban might reduce the risk of dementia. |
Keywords | Alzheimer’s disease
cerebral amyloid angiopathy
chronic cerebral hypoperfusion
rivaroxaban
white matter
|
Note | This is an Accepted Manuscript of an article published by IOS Press.
|
Published Date | 2023-11-07
|
Publication Title |
Journal of Alzheimer's Disease
|
Volume | volume96
|
Issue | issue2
|
Publisher | IOS Press
|
Start Page | 609
|
End Page | 622
|
ISSN | 1387-2877
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
File Version | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.3233/jad-230413
|
Citation | Bian, Zhihong et al. ‘Protective Effects of Rivaroxaban on White Matter Integrity and Remyelination in a Mouse Model of Alzheimer’s Disease Combined with Cerebral Hypoperfusion’. 1 Jan. 2023 : 609 – 622.
|
Funder Name |
Japan Agency for Medical Research and Development
|
助成番号 | 20K09370
20K12044
21K19572
20K19666
21K15190
|